3D Imaging Advances Lysosomal Disease Research

A recent study conducted by researchers from the Institute of Applied Sciences and Intelligent Systems (ISASI-CNR) and the Telethon Institute of Genetics and Medicine (TIGEM) has unveiled a revolutionary technique in the field of cellular imaging. The application of 3D holographic imaging has allowed for the tracking of lysosomal changes in live cells without the need for chemical labels, marking a significant advancement in the study of lysosomal storage diseases (LSDs).

Overview of the Study

Published in ACS Nano, this innovative approach harnesses holographic tomographic flow cytometry (HTFC) to quantitatively observe lysosomes in suspended live cells. The primary focus of the study centers around Niemann-Pick type C1 (NPC1), a lysosomal storage disorder that has profound implications for cellular health.

“For the first time, we can measure biophysical parameters of lysosomes—such as density and volume—and see how pathological accumulation of molecules alters their physical properties,” states Diego Medina, Principal Investigator at TIGEM.

Lysosomal Storage Diseases: An Introduction

Lysosomal storage diseases represent a group of over 60 rare genetic disorders caused by defective enzymes or proteins in lysosomes. These disorders pose severe impacts on various tissues and organs, particularly affecting the central nervous system. Current diagnostic tools are often inefficient due to the limitations of assessing lysosomal function in live cells.

The Role of HTFC

The HTFC technology, as developed in this study, provides a number of significant advantages:

• Label-free Imaging: This new method does not require staining or complex cell preparation, allowing for a more accurate representation of cells in a native state.
• High Resolution: The technology offers high-resolution, three-dimensional imaging, yielding detailed insights into the cellular architecture.
• Clinical Relevance: By utilizing suspended live cells, this approach closely mimics clinical environments, enhancing the applicability of findings.

Methodology

In this study, the researchers analyzed thousands of suspended cells, creating high-content 3D tomograms based on refractive index measurements. This generated significant insights into the morphological features of lysosomes, allowing for the identification of key morphometric biomarkers that differentiate healthy cells from those affected by diseases.

Implications for Treatment and Diagnostics

As the researchers monitor the effects of both pharmacological and genetic treatments, the HTFC method opens doors to new biomarkers for lysosomal storage disorders. The potential for clinical application is emphasized by the prospect of implementing this technology in the validation processes for patient-derived cells, such as fibroblasts and blood cells.

Future Directions

The team is engaged in further refining this technology to achieve single-lysosome identification, which would blend high-resolution microscopy with large-scale statistical analysis—an important step towards enhancing diagnostic and therapeutic approaches.

“The integration of holographic cytometry into the translational research pipeline is a crucial step toward operationalizing these methods in clinical settings,” remarks Pietro Ferraro, Research Director at ISASI-CNR.

Conclusion

In summary, the application of 3D holographic imaging has substantially advanced our capability to investigate lysosomal dynamics in live cells, offering substantial promise for more effective diagnostics and treatment strategies for lysosomal storage diseases. This research marks a significant leap toward better understanding and managing these complex disorders.

References

Daniele Pirone et al, Drug-Induced Reversible Lysosomal Changes Tracked in Live Cells by Holo-Tomographic Flow Cytometry, ACS Nano (2025).

For more information, visit the article at Phys.org.